CATALYST DOSSIER · UPDATED 2026-11-05
$VTAK
biotech · convergence -12 · conviction AVOID
Price & Live Quote Loading live quote & chart…
Practice trade tools Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $VTAK?
Quantitative
Net Income (CY2026Q2) : $-3.3M (+35.5% YoY)
Catalysts
Multi-spoke convergence : 3 convergent signals fired: auto_macro_adp_payrolls, auto_macro_durable_goods, auto_macro_fx_rates
Risks
Position-sizing discipline : Conviction AVOID (-12 score) — size accordingly; no specific catalyst-fade risk flagged
Bear case
Multiple compression : If breadth deteriorates, biotech-wide multiples re-rate lower regardless of pick-specific thesis
Sympathy basket (cerebro)
APP via tech r=+0.81 sympathetic (score 19)
STEM via tech r=+0.81 sympathetic (score 19)
LBTYA via comms r=+0.62 sympathetic (score 16)
CHTR via comms r=+0.62 sympathetic (score 7)
Signals Firing
auto_macro_adp_payrolls auto_macro_durable_goods auto_macro_fx_rates
Pick Track Record Date List Next-day max run Next-day close Hit +2%? 2026-10-14 sec_clean_gappers +11.4% +11.4% ✓ hit 2026-10-14 sec_top_gappers +11.4% +11.4% ✓ hit 2026-10-14 sec_top_moat_emerging +11.4% +11.4% ✓ hit 2026-10-13 sec_top_gappers -5.7% -17.0% — 2026-10-13 sec_top_moat_emerging -5.7% -17.0% — 2026-10-12 sec_top_gappers +10.0% +6.0% ✓ hit 2026-10-12 sec_top_moat_emerging +10.0% +6.0% ✓ hit 2026-10-05 sec_top_gappers -21.6% -36.4% — 2026-10-05 sec_top_moat_emerging -21.6% -36.4% — 2026-10-02 sec_top_gappers +13.3% +8.0% ✓ hit 2026-10-02 sec_top_moat_emerging +13.3% +8.0% ✓ hit
Lifetime: 7/11 wins · hit-rate 63.6% on +2% intraday
Sympathy Basket APP via tech · score 19 STEM via tech · score 19 LBTYA via comms · score 16 CHTR via comms · score 7
Earnings Catalyst No recent earnings event.
Generate full earnings report
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks
and its losses — see the
trust report and
methodology .
Not financial advice. Confirm independently before trading.